Nab-Paclitaxel ± CC-486 as Second-Line Treatment of Advanced NSCLC: Results from the ABOUND.2L+Study

被引：0
|
作者：
Morgensztern, D. [1 ]
Cobo Dols, M. [2 ]
Ponce Aix, S. [3 ]
Postmus, P. E. [4 ]
Bennouna, J. [5 ]
Fischer, J. [6 ]
Vidal, O. [7 ]
Stewart, D. [8 ]
Fasola, G. [9 ]
Weaver, J. [10 ]
Wolfsteiner, M. [11 ]
Ong, T. J. [10 ]
Govindan, R. [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Hosp Reg Univ Carlos Haya, Gen Hosp, Malaga, Spain
[3] Unidad Invest Clin Canc Pulmon H12O Cnio, Madrid, Spain
[4] Clatterbridge Canc Ctr, Liverpool, Merseyside, England
[5] Ctr Rene Gauducheau, Ctr Lutte Canc Nantes Atlantique, Nantes, Loire Atlantiqu, France
[6] Lungenklin Lowenstein, Lowenstein, Baden Wurttembe, Germany
[7] Univ Politecn La Fe, Valencia, Spain
[8] Ottawa Hosp, Ottawa, ON, Canada
[9] Univ Hosp Santa Maria Della Misericordia, Udine, Italy
[10] Celgene Corp, Summit, NJ USA
[11] Pra Hlth Sci, Lenexa, KS USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
nab-paclitaxel; Second-line; CC-486;
D O I：
10.1016/j.jtho.2017.09.460
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA 03.01
引用
收藏
页码：S1806 / S1807
页数：2
相关论文
共 50 条
  • [1] Nab-Paclitaxel with or without CC-486 as Second-Line Therapy for NSCLC (ABOUND.2L)
    Govindan, Ramaswamy
    Ardizzoni, Andrea
    Eberhardt, Wilfried E. E.
    Garrido, Pilar
    Ko, Amy
    Morgensztern, Daniel
    Nikolinakos, Petros
    Ong, Teng Jin
    Wolfsteiner, Marianne
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S667 - S667
  • [2] Nab-Paclitaxel plus Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2L+
    Govindan, R.
    Dols, M. Cobo
    Aix, S.
    Postmus, P. E.
    Lewanski, C.
    Bennouna, J.
    Fischer, J.
    Vidal, O.
    Stewart, D.
    Ardizoni, A.
    Weaver, J.
    Wolfsteiner, M.
    Reck, M.
    Talbot, D.
    Morgensztern, D.
    Ong, T. J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1839 - S1840
  • [3] ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Morgensztern, D.
    Ong, T. J.
    Dols, M. Cobo
    Aix, S. Ponce
    Postmus, P. E.
    Lewanski, C.
    Bennouna, J.
    Fischer, J. R.
    Vidal, O. J.
    Stewart, D. J.
    Fasola, G.
    Ardizoni, A.
    Weaver, J.
    Wolfsteiner, M.
    Talbot, D.
    Govindan, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Nab-paclitaxel as second-line treatment in advanced biliary cancer
    Unseld, M.
    Kornek, G.
    Werner, S.
    Guenther, S.
    Christoph, Z.
    Gerald, P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S431 - S432
  • [5] ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC)
    Morgensztern, Daniel
    Cobo, Manuel
    Aix, Santiago Ponce
    Postmus, Pieter E.
    Lewanski, Conrad R.
    Bennouna, Jaafar
    Fischer, Juergen R.
    Juan-Vidal, Oscar
    Stewart, David J.
    Fasola, Gianpiero
    Ardizzoni, Andrea
    Bhore, Rafia
    Wolfsteiner, Marianne
    Talbot, Denis C.
    Ong, Teng Jin
    Govindan, Ramaswamy
    CANCER, 2018, 124 (24) : 4667 - 4675
  • [6] Second-line nab-paclitaxel for advanced urothelial carcinoma
    Sarah Payton
    Nature Reviews Urology, 2013, 10 (8) : 431 - 431
  • [7] Nab-paclitaxel as second-line treatment in advanced biliary cancer.
    Prager, Gerald W.
    Kornek, Gabriela
    Scheithauer, Werner
    Steger, Guenther G.
    Zielinski, Christoph
    Unseld, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [8] Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel plus Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+)
    Morgensztern, D.
    Govindan, R.
    Cobo, M.
    Ponce Aix, S.
    Postmus, P. E.
    Lewanski, C.
    Bennouna, J.
    Fischer, J.
    Juan-Vidal, O.
    Stewart, D.
    Ardizzoni, A.
    Bhore, R.
    Wolfsteiner, M.
    Reck, M.
    Talbot, D.
    Ong, T. J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S489 - S489
  • [9] Capecitabine and Nab-Paclitaxel as Second-Line Treatment for Advanced Biliary Tract Cancer (ABTC): Results from a Phase II Pilot Study
    Leighton, Carly
    Brungs, Daniel
    Sjoquist, Katrin
    Chantrill, Lorraine
    Grimison, Peter
    Tognela, Annette
    Aghmesheh, Morteza
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 127 - 127
  • [10] Safety and Efficacy Results From ABOUND.70+: nab-Paclitaxel/Carboplatin in Elderly Patients With Advanced NSCLC
    Langer, Corey
    Goldman, Jonathan
    Amiri, Kathy
    Anderson, Eric
    DakhiLs, Shaker
    Haggstrom, Daniel
    Jotte, Robert
    Konduri, Kartik
    Modiano, Manuel
    Ong, Teng
    Sanford, Alexandra
    Smith, David
    Socoteanu, Matei
    Kim, Edward
    Weiss, Jared
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S916 - S917
12345